The 4D Biomedical Advisory Board meets annually with the Consulting Team to review:
- The sector, trends and latest deals
- Progress on projects
Individual board members are available to be engaged on specific projects as agreed with clients.
The the Advisory Board is made up of leading figures from the field of UK Biomedicine, and meets annually with guests at its Foresight Dinner to review long term trends in the sector, with indisvidual members being availble to support particular projects from time to time as and when available, and their specialist skills are required.
Out-going Chair of the Board
George Freeman who created 4D, has been elected the MP for Mid-Norfolk. In taking this position and following the invitation from the Minister for Science and Universities to advise the Government on Life Science policy George has now given up all commercial interest in 4D-Biomedical with effect from the 30th September 2011.
Advisory Board Members
Dr Andy Richards
Andy Richards is a well known biotechnology entrepreneur and business angel. He is currently a director of Vectura Group plc, Biowisdom Ltd, Daniolabs Ltd, Theradeas Ltd, Cancer Research Technology Ltd (the commercial arm of CR-UK), Babraham Bioscience Technology Ltd, Babraham Bioconcepts Ltd and non-executive Chairman of Geneservice Ltd, Altacor Ltd and Pharmakodex Ltd.
His early career was with ICI (now AstraZeneca) and PA Technology. He was a founder of Chiroscience in 1992 and an executive director through to its merger with Celltech in August 1999. He also founded and invested in Arakis, Cambridge Biotechnology Ltd, Amedis Pharmaceuticals and Sirus Pharmaceuticals.
Andy is a founder member of the Cambridge Angels, a founder investor in Library House, a member of the Council of UEA, a director of the Bioindustry Association (BIA) and an advisor to Toscana Life Sciences. He was Cambridge Evening News Businessman of the Year in 2005.
Peter Keen is Corporate Development and Finance Director of Serentis Inc. He was formerly CFO of Arakis Ltd where he led the successful £106m trade sale; co-founder of Merlin Ventures and MD until 2003; and FD of Chiroscience plc where he oversaw the LSE listing.
Peter is Chairman, Non-Executive Director and adviser to a number of leading UK companies and funds, including Ark Therapeutics Group plc, Abcam plc, the Biotech Growth Trust plc and venture capital company DFJ Esprit.
Dr Ann Hayes
Ann Hayes worked for 22 years for GlaxoWellcome as a Director in Drug Discovery, with particular expertise in the areas of CNS and pain. Ann left GSK in 2001 and has co-founded three companies, Ionix Pharmaceuticals (which has been bought by Vernalis), Therasci (which has been bought by CeNeS), and Theradeas.
Ann is a Non-Executive Director for Curidium Ltd and Plethora Solutions plc, and a member of the advisory boards for Lectus Therapeutics, CeNeS, Paradigm, Ingenium and Neurosolutions. She has also held Non-Executive Director positions at Therasci, Ionix and Sirus (which was sold to Arakis). She consults for CeNes and Shire, as well as doing ad hoc consulting for a number of small companies and VCs. She lectures on the Masters in Bioscience Enterprise at Cambridge University.
Dr David Cotterell
David Cotterell is founder and MD of Apex Healthcare, the specialist pharmaceutical market research and product consulting house. He was at GlaxoSmithKline Beecham from 1990-1996. He holds a PhD and MBA.
Simon Cartmell is CEO of Apatech Ltd, a world leader in synthetic bone graft technologies. Previously he worked 17 years at GlaxoWellcome in a number of U.K. and global roles, including Therapy Area Director, Infectious Diseases and Hepatitis.
Simon joined Vernalis plc (formerly Vanguard Medica plc) as COO in 1998 overseeing its acquisition of Cerebrus plc in 1999. He joined the main board of Celltech plc in the role of CEO for Celltech Pharmaceuticals in mid 2000. More recently Simon has been interim CEO of Entomed sa, where he remains a Non-Executive Director. He is also Non-Executive Chairman of Curidium Ltd, an advisor to a number of Venture and Private Equity groups and a Sloan Fellow from London Business School.
Professor John Caldwell BPharm PhD DSc Hon MRCP CBiol FIBiol
Pro-Vice-Chancellor, University of Liverpool
John Caldwell is an internationally recognised toxicologist, with over 20 years leadership experience in biomedical research, medical education and health care. Educated in London, after academic posts at St Mary’s Hospital Medical School, he held leading senior academic appointments at Imperial College from 1991 – 2002 (including Dean of St Mary’s 1995 – 1997 and Head of Undergraduate Medicine 2000 – 2002) and then at the University of Liverpool (as Faculty Dean from 2002 – 2010), which have given him wide experience in academic management in research-led institutions. As well as fulfilling the specific responsibilities of his various posts, he has have taken on portfolio roles, notably in technology transfer, protection and exploitation of intellectual property and the development of national and international strategic partnerships with major public and private organisations. He has complemented this experience with work on the interface between universities and the National Health Service, serving as a Non-Executive Director at Strategic Health Authority level, engagement with regional economic development and as a director of various public and private companies. He also has maintained a portfolio of consultancy and advisory roles, as a member of the national and international government, industrial and investment advisory committees and boards.
Bryan Morton has a BSc in Pharmacology from Aberdeen University and an MBA from Durham University. He began his pharmaceutical career in sales and has held positions of increasing responsibility in medical information, marketing, sales management, business development and general management during a 30 year career in the healthcare industry, largely with Merck and Co. Inc. and Bristol Myers Squibb.
During this time he has lived and worked in the UK, USA, Australia and Belgium and in 2003 he founded Zeneus Pharma through the acquisition of Elan’s European sales and marketing business for $120m in a private equity deal.
Following the sale of Zeneus Pharma for $360m in late 2005, Bryan founded EUSA Pharma in 2006 with backing from Essex Woodlands Health Ventures